samedan logo
 
 
spacer
home > pmps > winter 2008 > get connected
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Get Connected

Mike Hurst at Baxa Corporation reviews the history of enteral feeding tube to IV line misconnections, and argues that the time is right for change

The recognition that IV and non-IV drugs should be administered in separate devices is supported by documentation of wrong-route medication errors in medical journal articles dating back to the late 1960s. The problem of misconnections, particularly enteral and breast milk being injected intravenously into neonates, still happens to this day despite warnings from virtually every affiliated professional and regulatory agency. This article argues that hospitals should do a top-to-bottom assessment of whether their systems can absolutely prevent non- IV fluid tubing from being misconnected to IV lines and take the appropriate measures to correct any deficiencies.

HISTORY

Journal articles dating back to the late 1960s and early 1970s discuss the issue of wrong-route medication errors. In the years since, many articles have been written on medical errors related to tubing misconnections. The Institute for Safe Medication Practices (1), for example, has written about oral to IV misconnections more than a dozen times since its inception in 1994. ISMP and other organisations have long advocated the use of non-luer connectors for administration of any nonparenteral drugs in order to prevent the possibility of an IV infusion of a non-sterile medication. Advocates for a new standard for enteral feeding include the Joint Commission on Hospital Accreditation (Joint Commission), which audits health systems for compliance to best practices, and the National Health Service (NHS) in the UK.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mike Hurst, RPh, MBA, is Vice President, Infusion Systems at Baxa Corporation. A national expert on syringe pump intermittent IV infusion technology, Mike successfully managed the Swedish Medical Center pharmacy in Seattle, and has 10 years’ experience as a pharmaceutical industry consultant. He developed dilution, compounding, drug solution expiration tables and IV pharmacy operational recommendations that set the standard for the most common intermittent syringe infusers. At Baxa, Mike has developed the Rapid Rate Infuser – the standard for Adenoscan infusion for cardiac stress monitoring. Currently, he supports business development and pharmacy process improvement activities. Mike holds a BS in Pharmacy from the University of Washington and an MBA from City University, Bellevue
spacer
Mike Hurst
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Medicines Discovery Catapult and ZEISS Set Sights on Advancing Microscopy

Driving the application of microscopy in drug discovery
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement